![Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.jp.7211823/MediaObjects/41372_2007_Article_BF7211823_Fig1_HTML.gif)
Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology
![A Pregnant Woman Never Drinks Alone. Visit zeroexposure.org The Zero Exposure Project Presented by Lisa Colen, MHA ZEP Director. - ppt download A Pregnant Woman Never Drinks Alone. Visit zeroexposure.org The Zero Exposure Project Presented by Lisa Colen, MHA ZEP Director. - ppt download](https://images.slideplayer.com/15/4579687/slides/slide_25.jpg)
A Pregnant Woman Never Drinks Alone. Visit zeroexposure.org The Zero Exposure Project Presented by Lisa Colen, MHA ZEP Director. - ppt download
![Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1086-y/MediaObjects/41591_2020_1086_Fig1_HTML.png)
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine
![Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ea575e6623c8d2b583ae75e04c4cfe32d08642c7/2-Figure1-1.png)
Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar
![Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01562-9/MediaObjects/41591_2021_1562_Fig1_HTML.png)
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine
![The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.jp.7211266/MediaObjects/41372_2005_Article_BF7211266_Fig1_HTML.gif)
The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology
![All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0a920e8d-fd31-4644-858c-66e668a32107/gr1.gif)
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology
![PPT - The Child Abuse Prevention and Treatment Act: Substance-exposed Births PowerPoint Presentation - ID:4965333 PPT - The Child Abuse Prevention and Treatment Act: Substance-exposed Births PowerPoint Presentation - ID:4965333](https://image2.slideserve.com/4965333/capta-issues-for-state-consideration4-l.jpg)
PPT - The Child Abuse Prevention and Treatment Act: Substance-exposed Births PowerPoint Presentation - ID:4965333
![PDF) The Challenges of Screening for Substance Use in Pregnant Women: Commentary on the 4P'S Plus Tool PDF) The Challenges of Screening for Substance Use in Pregnant Women: Commentary on the 4P'S Plus Tool](https://i1.rgstatic.net/publication/7826945_The_Challenges_of_Screening_for_Substance_Use_in_Pregnant_Women_Commentary_on_the_4P'S_Plus_Tool/links/53e893550cf2fb7487243b4f/largepreview.png)
PDF) The Challenges of Screening for Substance Use in Pregnant Women: Commentary on the 4P'S Plus Tool
![The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition - Journal of the American Medical Directors Association The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition - Journal of the American Medical Directors Association](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/20b1c165-89d7-48fc-a747-3a29152301ed/gr1_lrg.jpg)